Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MRKNASDAQ:SMMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMRKMerck & Co., Inc.$89.18+1.8%$91.92$81.04▼$134.63$221.28B0.3511.05 million shs12.39 million shsSMMTSummit Therapeutics$20.32-1.4%$20.51$2.10▼$33.89$14.99B-1.043.43 million shs1.69 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMRKMerck & Co., Inc.+1.81%-4.56%-0.23%-10.55%-32.31%SMMTSummit Therapeutics-1.36%+2.89%+11.04%+11.59%+441.87%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMRKMerck & Co., Inc.5 of 5 stars4.35.04.23.92.73.33.8SMMTSummit Therapeutics2.8149 of 5 stars4.52.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMRKMerck & Co., Inc. 2.65Moderate Buy$117.1231.33% UpsideSMMTSummit Therapeutics 3.00Buy$35.4474.43% UpsideCurrent Analyst Ratings BreakdownLatest SMMT and MRK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025SMMTSummit TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$23.00 ➝ $35.003/21/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/12/2025SMMTSummit TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.002/28/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$42.002/25/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.00 ➝ $44.002/18/2025MRKMerck & Co., Inc.Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$128.00 ➝ $105.002/12/2025MRKMerck & Co., Inc.GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$122.00 ➝ $115.002/10/2025MRKMerck & Co., Inc.TD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$121.00 ➝ $100.002/10/2025MRKMerck & Co., Inc.TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$121.00 ➝ $100.002/5/2025MRKMerck & Co., Inc.Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$118.00 ➝ $112.002/5/2025MRKMerck & Co., Inc.BMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Perform ➝ Market Perform$105.00 ➝ $96.00(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMRKMerck & Co., Inc.$64.17B3.51$3.09 per share28.82$14.85 per share6.01SMMTSummit Therapeutics$700K21,413.80N/AN/A$0.11 per share184.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMRKMerck & Co., Inc.$17.12B$6.7313.259.010.7726.67%45.35%17.36%4/24/2025 (Estimated)SMMTSummit Therapeutics-$614.93M-$0.31N/AN/AN/AN/A-85.42%-52.66%4/29/2025 (Estimated)Latest SMMT and MRK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/24/2025N/AMRKMerck & Co., Inc.$2.16N/AN/AN/A$15.59 billionN/A2/24/2025Q4 2024SMMTSummit Therapeutics-$0.08-$0.08N/A-$0.08N/A$0.20 million2/4/2025Q4 2024MRKMerck & Co., Inc.$1.85$1.72-$0.13$1.48$15.51 billion$15.62 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMRKMerck & Co., Inc.$3.243.63%+5.73%48.14%14 YearsSMMTSummit TherapeuticsN/AN/AN/AN/AN/ALatest SMMT and MRK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/28/2025MRKMerck & Co., Inc.quarterly$0.813.32%3/17/20253/17/20254/7/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMRKMerck & Co., Inc.0.791.361.15SMMTSummit TherapeuticsN/A8.318.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMRKMerck & Co., Inc.76.07%SMMTSummit Therapeutics4.61%Insider OwnershipCompanyInsider OwnershipMRKMerck & Co., Inc.0.09%SMMTSummit Therapeutics88.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMRKMerck & Co., Inc.69,0002.53 billion2.53 billionOptionableSMMTSummit Therapeutics110737.68 million86.28 millionOptionableSMMT and MRK HeadlinesRecent News About These CompaniesCitigroup Upgrades Summit Therapeutics (BMV:SMMT)March 28 at 12:38 PM | nasdaq.comCitigroup Upgrades Summit Therapeutics (SMMT)March 27 at 9:19 PM | msn.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Time to Buy?March 27 at 10:49 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Upgraded at CitigroupMarch 27 at 8:11 AM | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Raised to "Buy" at CitigroupMarch 27 at 3:37 AM | americanbankingnews.comWhy Summit Therapeutics Stock Slipped TodayMarch 26 at 5:21 PM | fool.comSummit Therapeutics upgraded ahead of lung cancer trial data readoutMarch 26 at 12:08 PM | proactiveinvestors.comS&P 500 Futures Decline in Premarket Trading; GameStop, Summit Therapeutics LeadMarch 26 at 8:09 AM | marketwatch.comIvyRock Asset Management HK Ltd Invests $2.97 Million in Summit Therapeutics Inc. (NASDAQ:SMMT)March 26 at 7:44 AM | marketbeat.comVirtu Financial LLC Sells 15,365 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT)March 26 at 4:23 AM | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Receives $34.11 Consensus Price Target from AnalystsMarch 26 at 2:57 AM | americanbankingnews.comAnalyst Initiates Coverage On 'Undervalued' Summit TherapeuticsMarch 24, 2025 | benzinga.comSummit Therapeutics (NASDAQ:SMMT) Earns Overweight Rating from Analysts at Cantor FitzgeraldMarch 24, 2025 | americanbankingnews.comIs Summit Therapeutics a Millionaire Maker?March 23, 2025 | fool.comSummit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Cantor FitzgeraldMarch 22, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by BrokeragesMarch 22, 2025 | marketbeat.comSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | businesswire.comSummit Therapeutics initiated with an Overweight at Cantor FitzgeraldMarch 21, 2025 | markets.businessinsider.comSummit Therapeutics (SMMT) Gets a Buy from Cantor FitzgeraldMarch 21, 2025 | markets.businessinsider.comThis Unstoppable Biotech Stock Just Became an Even Better BuyMarch 19, 2025 | msn.comSkandinaviska Enskilda Banken AB publ Takes Position in Summit Therapeutics Inc. (NASDAQ:SMMT)March 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMMT and MRK Company DescriptionsMerck & Co., Inc. NYSE:MRK$89.18 +1.58 (+1.80%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$89.15 -0.03 (-0.03%) As of 03/28/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.Summit Therapeutics NASDAQ:SMMT$20.32 -0.28 (-1.36%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$20.52 +0.20 (+0.98%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/24 - 03/28 JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
